Requip, Ropinirole News

RLS patients have to decide whether a drug's benefits will outweigh its risks. The television commercials will certainly tell you: Restless legs syndrome is out there, and so are the pills to treat it.

From the Department of Neurology , University of California, Irvine; Department of Neurology , University of California, Los Angeles; Department of Neurology , University of Texas, Houston; and Neurosciences MDC , GlaxoSmithKline, Research Triangle Park, NC.

Restless legs syndrome is a neurological disorder characterized by unpleasant sensations in the legs and an uncontrollable urge to move when at rest, in an effort to relieve these feelings.

Ranbaxy Pharmaceuticals Canada Inc. , a wholly owned subsidiary of Ranbaxy Laboratories Limited , announced today that RLL has received approval in Canada to manufacture and market Ran-Ropinirole 0.25 mg, 1.0 mg, 2.0 mg, and 5.0 mg tablets from Health Canada, Therapeutic Products Directorate .

Q: I was diagnosed with Restless Legs Syndrome 10 years ago and have been taking the common medications for this condition, which seems to control my symptoms most of the time.

Dr Martin Scurr has been treating patients for more than 30 years and is one of the country's leading GPs.

Evidence suggests the potential to improve motor status in patients with stroke by modifying brain catecholaminergic tone.

New data presented at the 13th International Congress of Parkinson's Disease and Movement Disorders show that Requip-Modutab* improves nocturnal symptoms experienced by patients with advanced Parkinson's disease .[i] The data showed that patients with more significant nocturnal symptoms had a greater improvement with Requip-Modutab, when used as an ...